drugset / Trial / NCT02539810
Renal Artery Stenting in Patients With Documented Resistant Hypertension and Atherosclerotic Renal Artery Stenosis (ANDORRA)
Phase 4
Terminated
4 enrolled
Assistance Publique - Hôpitaux de Paris
Ministry of Health, France · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
The ANDORRA study is a, multicenter, prospective, open, randomized, controlled blinded endpoint trial (PROBE) comparing two treatment strategies (renal artery stenting + standardized and optimized medical treatment \[SOMT\] versus SOMT alone) of 12 months duration in patients with confirmed resistant hypertension (RH) and angiographically proven grade III unilateral or bilateral atherosclerotic renal artery stenosis (ARAS) ≥ 60%.
Timeline
- Start
- 2015-09
- Primary completion
- 2016-12
- Completion
- 2017-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Amlodipine | Other / unclassified | 10 mg | — |
| Subject | Bisoprolol | Other / unclassified | 10 mg | — |
| Subject | Furosemide | Other / unclassified | 40 mg | — |
| Subject | Indapamide | Small molecule | 1.5 mg | — |
| Subject | Irbesartan | Small molecule | 300 mg | — |
| Subject | Prazosin | Unknown | 5 mg | — |
| Subject | Rilmenidine | Small molecule | 1 mg | — |
| Subject | Spironolactone | Small molecule | 12.5 mg | — |
| Subject | Spironolactone | Small molecule | 25 mg | — |
| Background | Aspirin | Small molecule | 75 mg | — |
| Background | Atorvastatin | Small molecule | 20 mg | — |
| Background | Clopidogrel | Small molecule | 75 mg | — |